ARTICLE | Company News

Intarcia terminates late-stage diabetes trials

February 9, 2018 4:24 PM UTC

Intarcia Therapeutics Inc. (Boston, Mass.) terminated two late-stage trials evaluating ITCA 650 in Type II diabetes, according to The company received a complete response letter from FDA in September for an NDA seeking approval in the indication (see BioCentury, Oct. 20, 2017).

An Intarcia spokesperson told BioCentury that a "clinical hold was put in place for ongoing marketing studies" and that trial data included in the company's NDA is not related to the terminated studies...

BCIQ Company Profiles

Intarcia Therapeutics Inc.